Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations.
EPM2A
EPM2B
Epilepsy
Lafora disease
Neurodegeneration
Progressive myoclonus
Journal
Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403
Informations de publication
Date de publication:
15 May 2021
15 May 2021
Historique:
received:
08
12
2020
revised:
22
02
2021
accepted:
17
03
2021
pubmed:
28
3
2021
medline:
15
5
2021
entrez:
27
3
2021
Statut:
ppublish
Résumé
Lafora disease (LD) is characterized by progressive myoclonus, refractory epilepsy, and cognitive deterioration. This complex neurodegenerative condition is caused by pathogenic variants in EPM2A/EPM2B genes, encoding two essential glycogen metabolism enzymes known as laforin and malin. Long-term follow-up data are lacking. We describe the clinical features and genetic findings of a cohort of 26 Italian patients with a long clinical follow-up. Patients with EPM2A/EPM2B pathogenic variants were identified by direct gene sequencing or gene panels with targeted re-sequencing. Disease progression, motor functions, and mental performance were assessed by a simplified disability scale. Spontaneous/action myoclonus severity was scored by the Magaudda Scale. Age range was 12.2-46.2 years (mean:25.53 ± 9.14). Age at disease onset ranged from 10 to 22 years (mean:14.04 ± 2.62). The mean follow-up period was 11.48 ± 7.8 years. Twelve out of the 26 (46%) patients preserved walking ability and 13 (50%) maintained speech. A slower disease progression with preserved ambulation and speech after ≥4 years of follow-up was observed in 1 (11%) out of the 9 (35%) EPM2A patients and in 6 (35%) out of the 17 (65%) EPM2B patients. Follow-up was >10 years in 7 (41.2%) EPM2B individuals, including two harbouring the homozygous p.(D146N) pathogenic variant. This study supports an overall worse disease outcome with severe deterioration of ambulation and speech in patients carrying EPM2A mutations. However, the delayed onset of disabling symptoms observed in the EPM2B subjects harbouring the p.(D146N) pathogenic variant suggests that the underlying causative variant may still influence LD severity.
Sections du résumé
BACKGROUND
BACKGROUND
Lafora disease (LD) is characterized by progressive myoclonus, refractory epilepsy, and cognitive deterioration. This complex neurodegenerative condition is caused by pathogenic variants in EPM2A/EPM2B genes, encoding two essential glycogen metabolism enzymes known as laforin and malin. Long-term follow-up data are lacking. We describe the clinical features and genetic findings of a cohort of 26 Italian patients with a long clinical follow-up.
METHODS
METHODS
Patients with EPM2A/EPM2B pathogenic variants were identified by direct gene sequencing or gene panels with targeted re-sequencing. Disease progression, motor functions, and mental performance were assessed by a simplified disability scale. Spontaneous/action myoclonus severity was scored by the Magaudda Scale.
RESULTS
RESULTS
Age range was 12.2-46.2 years (mean:25.53 ± 9.14). Age at disease onset ranged from 10 to 22 years (mean:14.04 ± 2.62). The mean follow-up period was 11.48 ± 7.8 years. Twelve out of the 26 (46%) patients preserved walking ability and 13 (50%) maintained speech. A slower disease progression with preserved ambulation and speech after ≥4 years of follow-up was observed in 1 (11%) out of the 9 (35%) EPM2A patients and in 6 (35%) out of the 17 (65%) EPM2B patients. Follow-up was >10 years in 7 (41.2%) EPM2B individuals, including two harbouring the homozygous p.(D146N) pathogenic variant.
CONCLUSIONS
CONCLUSIONS
This study supports an overall worse disease outcome with severe deterioration of ambulation and speech in patients carrying EPM2A mutations. However, the delayed onset of disabling symptoms observed in the EPM2B subjects harbouring the p.(D146N) pathogenic variant suggests that the underlying causative variant may still influence LD severity.
Identifiants
pubmed: 33773408
pii: S0022-510X(21)00102-7
doi: 10.1016/j.jns.2021.117409
pmc: PMC8166462
mid: NIHMS1698060
pii:
doi:
Substances chimiques
Ubiquitin-Protein Ligases
EC 2.3.2.27
Protein Tyrosine Phosphatases, Non-Receptor
EC 3.1.3.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117409Subventions
Organisme : NINDS NIH HHS
ID : P01 NS097197
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Epilepsy Behav. 2020 Feb;103(Pt A):106839
pubmed: 31932179
Hum Mol Genet. 2002 May 15;11(11):1263-71
pubmed: 12019207
Epilepsia. 2006 Mar;47(3):640-3
pubmed: 16529633
Epileptic Disord. 2012 Mar;14(1):94-8
pubmed: 22425593
Pediatr Neurol. 2001 Jul;25(1):21-9
pubmed: 11483392
Seizure. 2017 Oct;51:77-79
pubmed: 28818698
Nat Genet. 1998 Oct;20(2):171-4
pubmed: 9771710
Epilepsia. 2006 Apr;47(4):788-92
pubmed: 16650146
Epilepsia. 2014 Dec;55(12):e129-33
pubmed: 25270369
J Med Genet. 2003 Sep;40(9):671-5
pubmed: 12960212
J Biol Chem. 2018 May 11;293(19):7117-7125
pubmed: 29483193
Epilepsia Open. 2016 Aug 25;1(3-4):136-139
pubmed: 29588937
Epileptic Disord. 2016 Sep 1;18(S2):38-62
pubmed: 27702709
Epilepsia. 2005 Oct;46(10):1695-7
pubmed: 16190947
Clin Genet. 2016 Jan;89(1):104-8
pubmed: 25683376
Seizure. 2020 Dec;83:145-153
pubmed: 33152654
Cells. 2018 Jul 26;7(8):
pubmed: 30050012
Neurology. 2014 Feb 4;82(5):405-11
pubmed: 24384641
Neurol Res Pract. 2019;1:
pubmed: 32587944
PLoS One. 2011;6(6):e21294
pubmed: 21738631
Epilepsy Res. 2001 Sep;46(3):283-7
pubmed: 11518630
Neurology. 2007 Mar 27;68(13):996-1001
pubmed: 17389303
Neurology. 2005 Mar 22;64(6):982-6
pubmed: 15781812
J Neurol Sci. 2013 Feb 15;325(1-2):170-3
pubmed: 23317923
Hum Mol Genet. 1995 Sep;4(9):1657-63
pubmed: 8541857
J Med Genet. 2006 Sep;43(9):e48
pubmed: 16950819
Hum Mol Genet. 2018 Apr 1;27(7):1290-1300
pubmed: 29408991
Nat Genet. 2003 Oct;35(2):125-7
pubmed: 12958597
Nat Rev Neurol. 2018 Oct;14(10):606-617
pubmed: 30143794
Epilepsy Behav Case Rep. 2014 Jan 19;2:19-21
pubmed: 25667860
Epileptic Disord. 2020 Apr 1;22(2):233-236
pubmed: 32301727
Brain Res Brain Res Rev. 1999 Apr;29(2-3):265-95
pubmed: 10209236